Evidence map›Paper›PMID 16091143›Full record

ArticleRetrovirology2005

Phosphatidylserine treatment relieves the block to retrovirus infection of cells expressing glycosylated virus receptors.

David A Coil, A Dusty Miller

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David A CoilDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. coild@u.washington.edu
A Dusty Miller
Fred Hutch Cancer Center · US

Funding

UNRELATED AND HLA-MISMATCHED RELATED DONOR TRANSPLANTSP01HL036444 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAWLINGS, DAVID J · 1986 to 2010
$25.9M
TRANSDUCTION OF BABOON HEMATOPOIETIC STEM CELLSP50HL054881 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERNSTEIN, IRWIN · 1995 to 2004
$11.0M
PILOT STUDY--RETROVIRUS MEDIATED TRANSFER OF HUMAN GLUCOCEREBROSIDASE GENEP30DK047754 · NIDDK · UNIVERSITY OF WASHINGTON · PI MILLER, ARTHUR DUSTY · 1994 to 2008
$8.4M
NHLBI NIH HHS HL36444NHLBI NIH HHS HL54881NHLBI NIH HHS P01 HL036444NHLBI NIH HHS P50 HL054881NIDDK NIH HHS DK47754NIDDK NIH HHS P30 DK047754
6 · The paper itself

Abstract

backgroundA major determinant of retrovirus host range is the presence or absence of appropriate cell-surface receptors required for virus entry. Often orthologs of functional receptors are present in a wide range of species, but amino acid differences can render these receptors non-functional. In some cases amino acid differences result in additional N-linked glycosylation that blocks virus infection. The latter block to retrovirus infection can be overcome by treatment of cells with compounds such as tunicamycin, which prevent the addition of N-linked oligosaccharides.

resultsWe have discovered that treatment of cells with liposomes composed of phosphatidylserine (PS) can also overcome the block to infection mediated by N-linked glycosylation. Importantly, this effect occurs without apparent change in the glycosylation state of the receptors for these viruses. This effect occurs with delayed kinetics compared to previous results showing enhancement of virus infection by PS treatment of cells expressing functional virus receptors.

conclusionWe have demonstrated that PS treatment can relieve the block to retrovirus infection of cells expressing retroviral receptors that have been rendered non-functional by glycosylation. These findings have important implications for the current model describing inhibition of virus entry by receptor glycosylation.

Indexed as

AnimalsCHO CellsCricetinaeDose-Response Relationship, DrugGlycosylationHumansMiceNIH 3T3 CellsPhosphatidylserinesReceptors, VirusRetroviridaePhosphatidylserinesReceptors, Virus

Identifiers

PMID16091143
PMCPMC1201173
OpenAlexW2106646499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.